Challenge Your Exam Readiness With Our Free NAPLEX Practice Questions

Isotretinoin is highly teratogenic. Risk management (e.g., iPLEDGE in the U.S.) requires two negative pregnancy tests before initiation, monthly testing, and the use of two effective forms of contraception (or strict abstinence) during therapy and for a period after discontinuation. Option C captures these critical safeguards, aligning with stringent requirements designed to prevent fetal exposure. Option A is incomplete; while abstinence is an option, pregnancy testing and program compliance are still mandatory. Option B understates contraception requirements (two forms, not one) and still requires two baseline tests. Option D is dangerously incorrect; teratogenicity risk persists throughout early pregnancy exposure, and no “safe” window exists during treatment. Pharmacists must verify program compliance before dispensing, document counseling, and ensure patients understand timelines and acceptable contraceptive methods.